<DOC>
	<DOC>NCT00721812</DOC>
	<brief_summary>A First-Time-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers</brief_summary>
	<brief_title>A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Inclusion criteria: Healthy as determined by a responsible physician Male, or only for the RDF cohort female of nonchildbearing potential, between 18 and 65 years of age. Body weight greater than 50 kg (110 lbs) and BMI within the range 18.529.9 kg/m2 (inclusive). QTcB or QTcF &lt; 450 msec Capable of giving written informed consent Exclusion criteria: The subject has a positive prestudy drug/alcohol screen History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units Urinary cotinine levels indicative of active smoking or regular use of tobacco A positive prestudy Hepatitis B surface antigen or positive Hepatitis C antibody A positive test for HIV antibody The subject has participated in a clinical trial and has received an investigational product within 30 days, 5 halflives of the investigational product Exposure to more than four new chemical entities within 12 months Use of prescription or nonprescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices within 7 days Subject is receiving hormone replacement therapy History of sensitivity to any of the study medications History of sensitivity to heparin or heparininduced thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>IBD</keyword>
	<keyword>first time in humans</keyword>
	<keyword>Phase 1</keyword>
	<keyword>human volunteers</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>